

## The Nonhuman Primate Resource (NHPRR) of UMass Chan Medical School Licenses Novel Fc Silencing Technology from mAbsolve

August 22, 2024

The [Nonhuman Primate Reagent Resource](#) (NHPRR), part of the University of Massachusetts Medical School, and [mAbsolve](#), developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve's Fc silencing technology.

Fc-mediated immune effector activities are an important part of an antibody's natural function, but in many therapeutic and reagent antibodies these interactions are not desirable and can lead to catastrophic side effects. Many approaches to eliminate effector function have been developed, but none completely silence the unwanted binding to Fc gamma receptors. The new STR Fc silencing platform, developed by mAbsolve and described in a [recent PLOS One article](#), delivers the only truly silent Fc mutations described to date. The technology therefore has the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.

The mission of NHPRR is to facilitate the optimal use of nonhuman primate models in biomedical research by identifying, developing, characterizing, and producing reagents for monitoring or modulating immune responses. These reagents are then distributed worldwide to enable scientists to advance their research. This license agreement allows NHPRR to utilize mAbsolve's best-in-class Fc silencing technology in all their antibody reagents which their clients and collaborators can access.

"Precise species-translatable effector silencing is essential for developing antibodies with defined interactions across immune effector molecules in both human and nonhuman primate species, ensuring targeted action without interference from unintended immune responses," said Dr. Diogo Magnani, Director of NHPRR.

"mAbsolve is committed to improving the safety and effectiveness of therapeutic antibodies, and we strongly believe that STR technology can be of real benefit to a large proportion of antibody and Fc fusion proteins in development," said Dr. Ian Wilkinson, Chief Scientific Officer at mAbsolve. "Our STR mutations provide a truly silent Fc region across all species we have tested, including non-human primates. We look forward to working with NHPRR to enable them to develop and distribute reagents containing these mutations."

For more information, visit the [NHPRR](#) or [mAbsolve](#) websites.

### **About Nonhuman Primate Reagent Resource.**

The Nonhuman Primate Reagent Resource (NHPRR) has been a driver in advancing biological research with nonhuman primate models for 25 years. By distributing high-quality, specialized research antibodies, NHPRR has supported over 2,000 NIH grants, enabling fundamental discoveries such as the role of immunosuppression therapies in pig-to-primate xenotransplantation, the study of AIDS virus reservoirs in macaques, the identification of CD8+ T cells as critical for elite control in macaques, and the testing of immunological responses in early monkey models of COVID, contributing to the development of human vaccines. Visit [www.nhpreagents.org](http://www.nhpreagents.org) for more information.



**About mAbsolve Ltd.**

mAbsolve founded in the UK by pioneers of therapeutic antibody development and engineering from both Oxford and Cambridge. We have experienced the clinical challenges caused by incomplete silencing of antibodies using LALA, aglycosylated or IgG4 variants. To address this we have developed a best-in-class solution for silencing of antibody effector function. Our STR technology is the only truly silent Fc. Visit [www.mabsolve.com](http://www.mabsolve.com) for more information.

**Contact:**

Diogo Magnani  
Director, NHPRR  
[Diogo.Magnani@umassmed.edu](mailto:Diogo.Magnani@umassmed.edu)

Ian Wilkinson  
Chief Scientific Officer  
[wilkinson@mabsolve.com](mailto:wilkinson@mabsolve.com)

###